Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01636284 · ClinicalTrials.gov registry record · Phase 2
A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer
A Phase 2 study, sponsored by Jennerex Biotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT01636284 is a Phase 2 study that has completed, run by Jennerex Biotherapeutics. The registered enrollment target is 16 participants.
The verdict
NCT01636284, a Phase 2 study, has completed, sponsored by Jennerex Biotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study is to determine how effectively JX-594 (Pexa-Vec) will prolong life in patients with advanced Hepatocellular Carcinoma (HCC) who have not been previously treated with sorafenib, and the safe administration of JX-594 in five weekly IV infusions.
Interventions
- BIOLOGICAL JX-594 recombinant vaccina GM-CSF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2012-06 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01636284
The ClinicalTrials.gov registry entry for NCT01636284 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jennerex Biotherapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JX-594 recombinant vaccina GM-CSF is the first listed.
NCT01636284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01636284 about?
NCT01636284 is a clinical study titled "A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer". This study is to determine how effectively JX-594 (Pexa-Vec) will prolong life in patients with advanced Hepatocellular Carcinoma (HCC) who have not been previously treated with sorafenib, and the safe administration of JX-594 in five weekly IV infusions.
What is the current status of trial NCT01636284?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2012-06. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01636284?
The interventions under investigation include: JX-594 recombinant vaccina GM-CSF (BIOLOGICAL).
Who is sponsoring clinical trial NCT01636284?
This trial is sponsored by Jennerex Biotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.